Invion Ltd. · ASX:IVX
Invion — EMERGENCE 2026 Investment Conference
15 slides from Invion's conference presentation, Feb 19, 2026
Slide 1: ASX Announcement: Investment Conference Presentation
ASX ANNOUNCEMENT INVESTMENT CONFERENCE PRESENTATION MELBOURNE (AUSTRALIA) 19 February 2026: Invion Limited (ASX: IVX) (“Invion” or the “Company”) will be presenting at the EMERGENCE 2026 Investment Conference in Sydney today. Attached is the presentation that Invion’s Executive Chair and CEO, Prof T
Slide 2: Corporate Presentation February 2026
CORPORATE For personal use only PRESENTATION February 2026 ASX: IVX Next Generation Photodynamic Therapy (PDT) for Cancers and Infectious Diseases
Slide 3: Disclaimer
DISCLAIMER For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited (Company). In p
Slide 4: Company Highlights: Clinical Inflexion Point Across Multiple Cancers
COMPANY HIGHLIGHTS CLINICAL INFLEXION POINT ACROSS MULTIPLE CANCERS Clinical Results: Multiple Cancers For personal use only • Successful Ph II Prostate Cancer Results (investigator led trial) • Promising early results from ongoing Ph I/II Non-Melanoma Skin Cancer trial • Upcoming anogenital cancer
Slide 5: The Photosoft Advantage
THE PHOTOSOFTTM ADVANTAGE NEXT GENERATION IMPROVEMENT ON APPROVED PDTs For personal use only Photosoft is a ground-breaking technology Minimally invasive modality for treating cancer that overcomes many significant shortcomings that specifically identifies and destroys cancer & side effects of appro
Slide 6: Lead Cancer Drug Candidate INV043
LEAD CANCER DRUG CANDIDATE INV043 MULTIPLE CANCERS, ATTRACTIVE THERAPEUTIC PROFILE For personal use only Lead Cancer Drug Candidate: INV043 Effective in regressing multiple types of cancer in human trials and in vivo1 PhotosoftTM Potency: ~600x greater photoxicity than Talaporfin (widely used photos
Slide 7: Phase II Prostate Cancer Clinical Trial Results
PHASE II PROSTATE CANCER CLINICAL TRIAL RESULTS INVESTIGATOR-LED PROSTATE CANCER STUDY USING INV043* TREATMENT PROTOCOL SAFE AND WELL TOLERATED For personal use only ▪ 41 patients dosed (16 post-COVID with ▪ No serious adverse events and all adverse readouts, 25 during COVID lockdown limited events
Slide 8: Phase I/II Non-Melanoma Skin Cancer Trial
PHASE I/II NON-MELANOMA SKIN CANCER TRIAL SAFETY REVIEW COMMITTEE FINDINGS – INITIAL PATIENT GROUP Change in size of NMSC lesions Findings from Safety Review Committee (SRC) For personal use only treated and untreated lesions* (initial patient group of 6) ▪ No adverse events identified & no pain Unt
Slide 9: INV043 Fluoresces Cancers Under Violet Light
INV043 FLUORESCES CANCERS UNDER VIOLET LIGHT DIAGNOSTIC POTENTIAL Potential for INV043 to assist surgeons to more accurately remove cancers For personal use only Animal studies at Hudson Institute Patient 101-002 from Ph I/II NMSC Trial: Day 1 of the treatment • Primary pancreatic (Human PANC1) canc
Slide 10: Combination with Immune Checkpoint Inhibitors (ICI)
COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS (ICI) IMPROVING IMMUNOTHERAPY OUTCOMES, PARTNERSHIP POTENTIAL HUDSON INSTITUTE:. ~65% IMPROVEMENT IN PETER MAC: ~80% RESPONSE RATE For personal use only TUMOUR VOLUME (TNBC, INTRATUMORAL)2 vs. 12.5% ICI ONLY (ANAL SCC CANCER, TOPICAL)3 7/10, no measurabl
Slide 11: Cancer: Target Indications and Timeframes
CANCER: TARGET INDICATIONS AND TIMEFRAMES MULTIPLE CLINICAL TRIALS AND INDICATIONS DISEASE AREA 1H2024 2H2024 1H2025 2H2025 >CY26 For personal use only CANCER (HUMAN) Prostate Cancer (Funded by RMWC) Completed Follow up and monitoring Non-Melanoma Skin Cancers (Topical)1 Adaptive study design Anogen
Slide 12: Collaboration with Protect Animal Health
COLLABORATION WITH PROTECT ANIMAL HEALTH LUCRATIVE COMPANION ANIMAL MARKET OPPORTUNITY New Market Potential For personal use only • Reinforces Photosoft as a platform technology with multiple market opportunities • Invion has hundreds of proprietary Photosoft compounds in its Founded in 2019, listed
Slide 13: Creating Impact for Treating Cancers Globally
CREATING IMPACT FOR TREATING CANCERS GLOBALLY NEED FOR MORE AFFORDABLE NEW TREATMENTS Commercial Rationale for Photosoft For personal use only Cost of new FDA drugs in 2023 jumped 35% YoY at median price of US$300K1, Works across multiple cancers without need affordability impacts to personalise – p
Slide 14: Experienced Team
EXPERIENCED TEAM THE RIGHT EXPERTISE FOR SUCCESS PROF THIAN CHEW PROF ROBERT RAMSAY EXECUTIVE CHAIRMAN & CEO SCIENTIFIC ADVISOR For personal use only • Co-Founder, Chronic Airway Therapeutics • 30+ years research in cancer biology &translational medicine • Advisory Board, Stanford Medicine CARE • Se
Slide 15: For more information
For personal use only For more information, go to www.inviongroup.com Investor and Media enquiries: Thian Chew (Chairman & CEO) Brendon Lau (Investor & Media Relations) T: +61 3 9692 7222 M: +61 409 341 613 E: investor@inviongroup.com E: brendon.lau@inviongroup.com